Isabella Fermo

Isabella Fermo

Auto-generated profile, based on publicly available information

Isabella Fermo

Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2001 in The Lancet
Verified
Journal Article
Closed access
carmine zoccalicarmine zoccali
carmine zoccali
SBStefanie M Bode-Böger
Stefanie M Bode-Böger
FMFrancesca Mallamaci
Francesca Mallamaci
FBFrank Antonio Benedetto
Frank Antonio Benedetto
GTGiovanni Tripepi
Giovanni Tripepi
RBRainer H Böger
Rainer H Böger

7 October 2006 in Diabetologia
Verified
Journal Article
Closed access
PDF file
EBE. Bosi
E. Bosi
LML. Molteni
L. Molteni
MRM. G. Radaelli
M. G. Radaelli
LFL. Folini
L. Folini
IFI. Fermo
I. Fermo
Rita ParoniRita Paroni
Rita Paroni

1 February 2002 in Kidney International
Verified
Journal Article
Closed access
FMFrancesca Mallamaci
Francesca Mallamaci
carmine zoccalicarmine zoccali
carmine zoccali
GTGiovanni Tripepi
Giovanni Tripepi
IFIsabella Fermo
Isabella Fermo
FBFrancesco A. Benedetto
Francesco A. Benedetto
ASArmando Soldarini
Armando Soldarini

1 November 2006 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
PLPietro Lucotti
Pietro Lucotti
ESEmanuela Setola
Emanuela Setola
LMLucilla D. Monti
Lucilla D. Monti
EGElena Galluccio
Elena Galluccio
SCSabrina Costa
Sabrina Costa
PPPierMarco Piatti
PierMarco Piatti
Because chronic l-arginine supplementation improves insulin sensitivity and endothelial function in nonobese type 2 diabetic patients, the aim of this study was to evaluate the effects of a long-term oral l-arginine therapy on adipose fat mass (FM) and muscle free-fat mass (FFM) distribution, daily glucose levels, insulin sensitivity, endothelial function, oxidative stress, and adipokine release in obese type 2 diabetic patients with insulin resistance who were treated with a combined period of hypocaloric diet and exercise training. Thirty-three type 2 diabetic patients participated in a hypocaloric diet plus an exercise training program for 21 days. Furthermore, they were divided into two groups in randomized order: the first group was also treated with l-arginine (8.3 g/day), and the second group was treated with placebo. Although in the placebo group body weight, waist circumference, daily glucose profiles, fructosamine, insulin, and homeostasis model assessment index significantly decreased, l-arginine supplementation further decreased FM (P < 0.05) and waist circumference (P < 0.0001), preserving FFM (P < 0.03), and improved mean daily glucose profiles (P < 0.0001) and fructosamine (P < 0.03). Moreover, change in area under the curve of cGMP (second messenger of nitric oxide; P < 0.001), superoxide dismutase (index of antioxidant capacity; P < 0.01), and adiponectin levels (P < 0.02) increased, whereas basal endothelin-1 levels (P < 0.01) and leptin-to-adiponectin ratio (P < 0.05) decreased in the l-arginine group. Long-term oral l-arginine treatment resulted in an additive effect compared with a diet and exercise training program alone on glucose metabolism and insulin sensitivity. Furthermore, it improved endothelial function, oxidative stress, and adipokine release in obese type 2 diabetic patients with insulin resistance.

1 December 1994 in Metabolism
Verified
Journal Article
Closed access
PPP M Piatti
P M Piatti
FMF Monti
F Monti
IFI Fermo
I Fermo
LBL Baruffaldi
L Baruffaldi
RNR Nasser
R Nasser
GPG Pozza
G Pozza

15 November 1995 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
IFIsabella Fermo
Isabella Fermo
SDSilvana Vigano' D'ANgelo
Silvana Vigano' D'ANgelo
Rita ParoniRita Paroni
Rita Paroni
GMGiuseppina Mazzola
Giuseppina Mazzola
GCGiliola Calori
Giliola Calori
ADArmando D'ANgelo
Armando D'ANgelo
To evaluate the prevalence of moderate hyperhomocysteinemia and inherited thrombophilia disorders (congenital defects of the natural anticoagulant or fibrinolytic mechanisms) in patients with early-onset venous or arterial thromboembolic disease. Cross-sectional 2-year evaluation of consecutive unrelated patients with a history of venous or arterial occlusive disease occurring before the age of 45 years or at unusual sites, in the absence of local predisposing factors. Thrombosis research unit of a community hospital. 107 patients with venous thromboembolism (mean age at event, 32.9 +/- 11.9 years) and 50 patients with arterial occlusive disease (mean age at event, 31.1 +/- 10 years) who did not have acquired coagulation defects, overt cancer, or acquired conditions affecting methionine metabolism. Total plasma homocysteine (fasting levels), antithrombin III, protein C, protein S, activated protein C resistance, plasminogen, and heparin cofactor II were measured at least 3 months after the event. In 87 patients, total plasma homocysteine levels were also measured 8 hours after an oral methionine load was administered (L-methionine, 0.1 g/kg body weight). Ninety-fifth percentiles of the distribution of these variables were established in 60 apparently healthy persons; sex-specific ranges were used for protein S and total plasma homocysteine. Relatives of patients with laboratory abnormalities were studied to confirm inheritance of the defects. Moderate hyperhomocysteinemia was detected in 13.1% (95% CI, 7.6% to 21.3%) and in 19.2% (CI, 9.0% to 31.9%) of patients with venous or arterial occlusive disease. The prevalence of hyperhomocysteinemia was almost twice as high when based on homocysteine measurements done after oral methionine load as when based on fasting levels. The remaining defects were detected only in patients with venous occlusive disease (activated protein C resistance in 11.2% of patients, protein S or C deficiency in 6.6%, and plasminogen deficiency in 0.9%), with an overall prevalence of 18.7% (CI, 12.1% to 27.6%). Inheritance of hyperhomocysteinemia and of the other defects was confirmed in 26 of the 30 families studied. Event-free survival analysis showed that the relative risk for occlusive disease in patients with moderate hyperhomocysteinemia and other defects was 1.70 times (CI, 1.19 to 2.42; P < 0.01) greater than in patients without defects. After adjustment for the presence of predisposing factors (for example, use of contraceptive drugs, pregnancy, surgery, prolonged bedrest, smoking, mild hypertension or dyslipidemia) and a family history of thrombosis, the age at first event of patients with moderate hyperhomocysteinemia was similar to that of patients with the other defects (26.4 +/- 11.2 years compared with 25.2 +/- 10.6 years), and the 43 patients with defects were significantly younger at first event than the 114 patients without defects (25.5 +/- 11.1 years compared with 31.0 +/- 12.3; P < 0.005). Patients with mild hyperhomocysteinemia had a higher rate of recurrence than those without defects (52% compared with 25%; P = 0.01); among the 56 patients who had their first event more than 1 year before observation, the recurrence rate was higher (80% [CI, 51% to 95%]) in patients with defects than in patients without defects (41% [CI, 26% to 57%] P = 0.01). Moderate hyperhomocysteinemia may have pathogenic significance in premature venous and arterial occlusive disease and should be included among the (inherited) disorders of venous and arterial thrombophilia.